8-K filed Sep 3, 2026 at 09:21 ET
Partner Akeso announced statistically significant overall survival (OS) benefit for ivonescimab monotherapy vs pembrolizumab in the Phase III HARMONi-2 study (PD-L1-positive advanced NSCLC, China). HARMONi-2 already met its primary PFS endpoint (HR 0.51, p<0.0001) and received NMPA approval in China in April 2025. The OS win adds to ivonescimab's favorable risk/reward profile ahead of Summit's November 14, 2026 PDUFA date for HARMONi (EGFR-mutated NSCLC), while Summit's own HARMONi-7 global monotherapy study in PD-L1-high NSCLC is enrolling. This cross-filing positive readout supports Summit's ivonescimab franchise but remains a single-region China study, the pivotal confirmatory data for US/Europe approval will come from Summit's HARMONi trial.